Fig. 1

Longitudinal assessment of global methylation uncovers low-intra subject variability. A cfDNA concentration (ng/µL) and proportion of prostate content (%) for forty-eight cfDNA samples. cfDNA concentration ranged from 0.61 to 38 ng/µL and prostate content from 0 to 49.1%. B Principal component analysis of the 801,849 EPIC array probes available after QC and pre-processing of raw data depicts the methylation differences between the 9 subjects at different timepoints. C Temporal probe variability for each subject. Gold circles represent the top 5% most variable probes. BL Baseline, cfDNA cell-free DNA, FU follow-up, mCRPC metastatic castration resistant prostate cancer, mPCa metastatic prostate cancer, NTS new treatment strategy, SD standard deviation